As a competitor encroached, mylan took one state to court to push epipen sales, documents show
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
The pharmaceutical company Mylan has developed a reputation for fighting tooth-and-nail to promote its flagship product, the EpiPen. Mylan has contended that its intensive marketing efforts
save lives. But over the past year, the public has started to question whether the company’s business tactics are in line with the best interests of patients. Now STAT has learned of yet
another previously unreported legal maneuver employed by the company to force one state to drive even more sales to its EpiPen, an epinephrine auto-injector used to halt potentially
life-threatening allergic reactions. STAT+ Exclusive Story Already have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS IN-DEPTH ANALYSIS,
NEWSLETTERS, PREMIUM EVENTS, AND NEWS ALERTS. Already have an account? Log in Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+. Subscribe